Literature DB >> 3882216

Preoperative short-term radiotherapy in rectal carcinoma. A preliminary report of a prospective randomized study.

B Cedermark, N O Theve, A Rieger, B Wahren, J E Glas, C Rubio, A Ost, L Broström, G Ekelund, L Forsgren.   

Abstract

Between 1980 and 1983, 373 patients with clinically resectable rectal adenocarcinoma entered a prospective randomized study aimed to evaluate the effect of short-term preoperative radiotherapy. Protocol violations were identified in 21 instances. Of the remaining 352 patients, 182 were randomized to surgical treatment only (S-group). Immediately, before surgery, 170 patients were irradiated to the pelvic region with 25 Gy (2500 rad) during a 5-day period (RT-group). Of these patients, 59% underwent abdominoperineal excision, 38% anterior resection, and 3% laparotomy only. At surgery distant metastases were discovered in 32 patients (9%). There were no significant differences between the groups in the distribution of age, sex, operative methods, and tumor stage according to the original Dukes' classification. During the follow-up time, ranging between 6 months and 3 years, tumor recurrence occurred in 35 patients, 19 in the S-group and 16 in the RT-group. Fifteen patients in the S-group had pelvic recurrence compared to 10 patients in the RT-group. Distant metastases occurred in six and eight patients, respectively. Two patients in each group had both pelvic and distant recurrence. There was no correlation between tumor recurrence and type of operation. Median time interval from diagnosis to pelvic recurrence was 10 months in the S-group and 16 months in the RT-group. Postoperative complications in the form of wound sepsis were slightly more common in the RT-group. In summary, the applied treatment regimen, is well-tolerated and apparently does not affect the Dukes' stage of the tumor. Although there is no statistically significant difference, there is a trend of less pelvic recurrence in patients receiving preoperative radiotherapy.

Entities:  

Mesh:

Year:  1985        PMID: 3882216     DOI: 10.1002/1097-0142(19850315)55:6<1182::aid-cncr2820550607>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  A Gérard; M Buyse; B Nordlinger; J Loygue; F Pène; P Kempf; J F Bosset; M Gignoux; J P Arnaud; C Desaive
Journal:  Ann Surg       Date:  1988-11       Impact factor: 12.969

2.  Adjuvant treatment in colorectal cancer: an update.

Authors:  H O Douglass
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

3.  Preoperative radiotherapy in rectal cancer.

Authors:  W Duncan
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

4.  Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after preoperative irradiation.

Authors:  Eva Angenete; Marcus Langenskiöld; Peter Falk; Marie-Louise Ivarsson
Journal:  Int J Colorectal Dis       Date:  2006-11-16       Impact factor: 2.571

Review 5.  Adjuvant therapy for colorectal carcinoma.

Authors:  U Metzger
Journal:  World J Surg       Date:  1991 Sep-Oct       Impact factor: 3.352

6.  Transforming growth factor beta-1 in rectal tumour, mucosa and plasma in relation to radiotherapy and clinical outcome in rectal cancer patients.

Authors:  Eva Angenete; Marcus Langenskiöld; Ingrid Palmgren; Peter Falk; Tom Oresland; Marie-Louise Ivarsson
Journal:  Int J Colorectal Dis       Date:  2007-07-27       Impact factor: 2.571

7.  Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma.

Authors:  Iosief Abraha; Cynthia Aristei; Isabella Palumbo; Marco Lupattelli; Stefano Trastulli; Roberto Cirocchi; Rita De Florio; Vincenzo Valentini
Journal:  Cochrane Database Syst Rev       Date:  2018-10-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.